1. Home
  2. CNTA vs KNSA Comparison

CNTA vs KNSA Comparison

Compare CNTA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTA
  • KNSA
  • Stock Information
  • Founded
  • CNTA 2020
  • KNSA 2015
  • Country
  • CNTA United Kingdom
  • KNSA United Kingdom
  • Employees
  • CNTA N/A
  • KNSA N/A
  • Industry
  • CNTA Biotechnology: Pharmaceutical Preparations
  • KNSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNTA Health Care
  • KNSA Health Care
  • Exchange
  • CNTA Nasdaq
  • KNSA Nasdaq
  • Market Cap
  • CNTA 1.9B
  • KNSA 1.9B
  • IPO Year
  • CNTA 2021
  • KNSA 2018
  • Fundamental
  • Price
  • CNTA $16.81
  • KNSA $31.98
  • Analyst Decision
  • CNTA Strong Buy
  • KNSA Strong Buy
  • Analyst Count
  • CNTA 11
  • KNSA 6
  • Target Price
  • CNTA $28.90
  • KNSA $40.83
  • AVG Volume (30 Days)
  • CNTA 1.1M
  • KNSA 648.4K
  • Earning Date
  • CNTA 08-12-2025
  • KNSA 07-29-2025
  • Dividend Yield
  • CNTA N/A
  • KNSA N/A
  • EPS Growth
  • CNTA N/A
  • KNSA N/A
  • EPS
  • CNTA N/A
  • KNSA 0.07
  • Revenue
  • CNTA $15,000,000.00
  • KNSA $529,332,000.00
  • Revenue This Year
  • CNTA N/A
  • KNSA $37.21
  • Revenue Next Year
  • CNTA N/A
  • KNSA $6.10
  • P/E Ratio
  • CNTA N/A
  • KNSA $484.58
  • Revenue Growth
  • CNTA 118.88
  • KNSA 56.18
  • 52 Week Low
  • CNTA $9.10
  • KNSA $17.82
  • 52 Week High
  • CNTA $19.09
  • KNSA $32.13
  • Technical
  • Relative Strength Index (RSI)
  • CNTA 67.45
  • KNSA 67.77
  • Support Level
  • CNTA $15.05
  • KNSA $26.27
  • Resistance Level
  • CNTA $17.69
  • KNSA $31.92
  • Average True Range (ATR)
  • CNTA 0.77
  • KNSA 1.12
  • MACD
  • CNTA 0.08
  • KNSA 0.37
  • Stochastic Oscillator
  • CNTA 70.10
  • KNSA 97.11

About CNTA Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Share on Social Networks: